Lenalidomid Teva B.V.

Lenalidomide, the active ingredient in Lenalidomid Teva B.V., is a Immunomodulatory imide drug (IMiD) presented as an oral tablet for oral use. It treats multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomid Teva B.V. as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Lenalidomide is employed in hematologic malignancies that involve abnormal plasma or lymphoid cells. - Multiple Myeloma: improves progression‑free survival and reduces disease burden in adult patients. - Myelodysplastic Syndromes with del(5q): induces transfusion independence and cytogenetic remission. - Mantle Cell Lymphoma: provides disease control in relapsed or refractory cases.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require fluid replacement. - Rash: mild skin eruptions or itching. - Neutropenia: reduced neutrophil count increasing infection risk.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Secondary malignancies: development of new cancers such as acute myeloid leukemia.

When prescribing Lenalidomide, clinicians should observe several safety precautions. - Pregnancy risk: contraindicated in pregnancy (Category X); ensure effective contraception. - Thromboembolic prophylaxis: assess need for anticoagulation in high‑risk patients. - Renal impairment: adjust monitoring and dose in patients with reduced kidney function. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Infection monitoring: watch for signs of infection due to neutropenia. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Lenalidomide has known drug interactions that may alter its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce plasma concentrations. - Anticoagulants (e.g., warfarin): increased risk of bleeding when combined with thrombocytopenia.

Moderate Interactions (Monitor Closely): - P‑glycoprotein inhibitors (e.g., verapamil): may increase exposure. - Immunosuppressants (e.g., cyclosporine): heightened risk of infection. - Live vaccines: may be less effective while on therapy.